

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:27:05 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 119 TO ITERATE

100.0% PROCESSED 119 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1726 TO 3034  
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 17:27:20 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 2285 TO ITERATE

100.0% PROCESSED 2285 ITERATIONS 42 ANSWERS  
SEARCH TIME: 00.00.01

L3 42 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 17:27:24 ON 10 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15  
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4                    6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:717059 CAPLUS

DOCUMENT NUMBER: 137:247710

TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents

INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPL. INFO.:			US 2000-214983P	20000629
OTHER SOURCE(S):		MARPAT 137:247710		

GI



AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20

.mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.

IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

antiinflammatory and immunosuppressive agents)


RN 388117-63-3 CAPLUS

CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-64-4 CAPLUS

CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS


CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS


CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-67-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-68-8 CAPLUS


CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-69-9 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-70-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-71-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS  
CN 4-Pyrimidinamine, N-[3-[(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-74-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-79-1 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-[(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS  
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-81-5 CAPLUS  
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-76-8 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 388117-77-9 CAPLUS  
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-[(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS  
CN Pyrimidine, 4-[4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
 CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388118-57-8P 388118-58-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)  
 RN 388118-57-8 CAPLUS  
 CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388118-58-9 CAPLUS  
 CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:449662 CAPLUS  
 DOCUMENT NUMBER: 137:33310  
 TITLE: Preparation of anilinoypyrimidines as IKK inhibitors  
 INVENTOR(S): Koike, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shrikant S.; Parnes, Jason S.; Palanki, MORTHY S. S.; Erdman, Paul E.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 194 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020195	A5	20020618	AU 2002-20195	20011205
PRIORITY APPLN. INFO.:		US 2000-251816P	P	20001206
		WO 2001-US46403	W	20011205
OTHER SOURCE(S):		MARPAT 137:33310		
GI				



AB The title compds. (I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCOR9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4) having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of 1.0 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.  
 IT 434944-90-8P 434945-04-7P 434945-05-8P 434945-27-4P 434950-45-5P 434950-46-6P


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434950-47-7P 434950-48-8P 434950-49-9P  
434950-50-2P 434950-51-3P 434950-52-4P  
434950-53-5PRL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(prepn. of anilinopyrimidines as IKK inhibitors)

RN 434944-90-8 CAPLUS


CN Benzamide

4-[[4-[[4-(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-  
(9CI) (CA INDEX NAME)

RN 434945-04-7 CAPLUS

CN Benzamide, 4-[[4-[[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA  
INDEX NAME)

RN 434945-05-8 CAPLUS


CN Benzamide, 4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)

RN 434945-27-4 CAPLUS


CN Morpholine, 4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-48-8 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-49-9 CAPLUS

CN Piperazine, 1-methyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

RN 434950-50-2 CAPLUS


CN Piperazine, 1-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

● 2 HCl


RN 434950-51-3 CAPLUS

CN 1-Piperazinepropanamine,  
N,N-dimethyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS

CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


RN 434950-46-6 CAPLUS

CN Piperazine, 1-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]-4-[[4-(tetrahydro-2-furanyl)methyl]- (9CI) (CA  
INDEX NAME)


RN 434950-47-7 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS


CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

RN 434950-53-5 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-  
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:449661 CAPLUS  
 DOCUMENT NUMBER: 137:33309  
 TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors  
 INVENTOR(S): Koia, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palenki, Moorthy S. S.; Erdman, Paul E.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 199 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205
OTHER SOURCE(S): MARPAT 137:33309				
GI				




AB The title comds. [I: R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)ACOR9, (CH2)ACOR9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of 1.0 μM in the JNK2 assay, was given. Such comds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical comds.


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-45-5 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
 CN Piperazine, 1-[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[[4-(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-48-8 CAPLUS

Habte

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 contg. one or more comds. of the above comds.

IT 434944-90-8P 434945-04-7P 434945-05-8P  
 434945-27-4P 434950-45-5P 434950-46-6P  
 434950-47-7P 434950-48-8P 434950-49-9P  
 434950-50-2P 434950-51-3P 434950-52-4P  
 434950-53-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilinopyrimidines as JNK pathway inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,


4-[[4-[[4-[[4-(chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS

CN Benzamide,


4-[[4-[[4-[[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-05-8 CAPLUS

CN Benzamide,

4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine,

4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-49-9 CAPLUS

CN Piperazine,


1-methyl-4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS

CN Piperazine,

1-[4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 434950-51-3 CAPLUS

CN 1-Piperazinepropanamine,


N,N-dimethyl-4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

4/8/2003


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS  
 CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




RN 434950-53-5 CAPLUS  
 CN Benzamide, N,N-dimethyl-4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31429 CAPLUS  
 DOCUMENT NUMBER: 136:102394  
 TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
 INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
 PATENT ASSIGNEE(S): Abbott Lab., USA  
 SOURCE: PCT Int. Appl., 135 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-606717 A 20000629 WO 2001-US20128 W 20010622				
OTHER SOURCE(S): MARPAT 136:102394				
GI				




AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 nM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COME, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.  
 IT 388118-57-8P 388118-58-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting


antiinflammatory and immunosuppressive agents)  
 RN 388118-57-8 CAPLUS  
 CN 4(1H)-Pyrimidinone, 6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS  
 CN Pyrimidine, 4-chloro-6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)  
 RN 388117-63-3 CAPLUS  
 CN Morpholine, 4-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-64-4 CAPLUS  
 CN 4-Piperidinol, 1-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-

Habe


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-65-5 CAPLUS  
 CN Morpholine, 2,6-dimethyl-4-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-67-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




4/8/2003




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RN 388117-68-8 CAPLUS  
 CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-70-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-74-6 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-76-8 CAPLUS  
 CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-71-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-73-5 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-77-9 CAPLUS  
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-78-0 CAPLUS  
 CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 388117-79-1 CAPLUS  
 CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RN 388117-80-4 CAPLUS  
 CN 3-Piperidinethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS  
 CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
 CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 388117-83-7 CAPLUS  
 CN Pyrimidine, 4-[[2R]-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 Absolute stereochemistry.



RN 388117-84-8 CAPLUS  
 CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 388117-85-9 CAPLUS  
 CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1992:612432 CAPLUS  
 DOCUMENT NUMBER: 117:212432  
 TITLE: Studies on cerebral protective agents. I. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities  
 AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshie; Kateuta, Kiyotaka; Kamitani, Toshiharu; Takasugi, Hisashi  
 CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan  
 SOURCE: Chemical & Pharmaceutical Bulletin (1992), 40(6), 1452-61  
 CODEN: CPBTAL; ISSN: 0009-2363  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Novel 4-arylpyrimidine derivs. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O2NC6H4) has ALP activity (73% inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of vitamin E.

IT 103293-67-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn., antianoxic and antilipid peroxidn. activities of)

RN 103293-67-0 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-[2-[[4-chlorophenyl]thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1986:572492 CAPLUS  
 DOCUMENT NUMBER: 105:172492  
 TITLE: Pyrimidine derivatives  
 INVENTOR(S): Takaya, Takao; Takasugi, Hisaoshi; Kuno, Atsushi;  
 Sugiyama, Yoshie  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 192 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
FI 8502796	A	19860120	FI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
FI 8503698	A	19860402	FI 1985-3698	19850926
EP 177287	A2	19860409	EP 1985-306880	19850927
EP 177287	A3	19861126		
EP 177287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58897	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001
PRIORITY APPLN. INFO.:			GB 1984-18380	19840719
			GB 1984-24711	19841001
			GB 1985-9623	19850415
			GB 1985-9633	19850415
			EP 1985-305143	19850718
			EP 1985-306880	19850927

GI

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Pyrimidines I (R = substituted aryl; R<sub>1</sub> = CO<sub>2</sub>H, esterified CO<sub>2</sub>H, alkanoyl, etc.; R<sub>2</sub> = H, aryl, alkyl, etc.; R<sub>3</sub> = alkyl, aryl) were prepd., and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine deriv. II was heated with MnO<sub>2</sub> to give I (R = 4-pyridyl, R<sub>1</sub> = CO<sub>2</sub>Et, R<sub>2</sub> = Me, R<sub>3</sub> = Ph). II was prepd. from an α-(arylmethylene)acetoacetate ester and an amidine.  
 IT 103293-67-09  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, for treatment of cerebrovascular disease)  
 RN 103293-67-0 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.63

175.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.91

-3.91

STN INTERNATIONAL LOGOFF AT 17:27:58 ON 10 APR 2003

Narrow  
search

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=&gt;


Uploading 09888840narrow.str

L1 STRUCTURE UPLOADED

=&gt; d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 10:17:53 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3 TO 163  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 10:18:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

L3 1 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 10:18:08 ON 08 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2003 VOL 138 ISS 15

FILE LAST UPDATED: 7 Apr 2003 (20030407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s l3

L4 2 L3

=&gt; d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:717059 CAPLUS

DOCUMENT NUMBER: 137:247710

TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents

INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983P P	20000629
OTHER SOURCE(S):		MARPAT 137:247710		
GI				



AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.


IT 388117-75-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31429 CAPLUS

DOCUMENT NUMBER: 136:102394

TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents

INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S): Abbott Lab.; USA

SOURCE: PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1294704 A1 20030326 EP 2001-946705 20010622  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 PRIORITY APPLN. INFO.: US 2000-606717 A 20000629  
 WO 2001-US20128 W 20010622  
 OTHER SOURCE(S): MARPAT 136:102394  
 GI



AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.


IT 388117-75-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

Habte


4/8/2003



	ENTRY	SESSION
FULL ESTIMATED COST	9.49	157.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 10:18:32 ON 08 APR 2003

*Broad Search*



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:33:30 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2803 TO ITERATE

35.7% PROCESSED 1000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 52886 TO 59234  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 17:33:39 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 55054 TO ITERATE

100.0% PROCESSED 55054 ITERATIONS 107 ANSWERS  
SEARCH TIME: 00.00.02

L3 107 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:33:50 ON 10 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15  
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 6 L3

=> d ibib abs histr tot

'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, IPC, and NCL  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and

its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs


To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:717059 CAPLUS  
DOCUMENT NUMBER: 137:247710  
TITLE: Preparation of aryl phenylheterocyclyl sulfides as  
cell adhesion-inhibiting anti-inflammatory and  
immune-suppressive agents  
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 44 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983 P	20000629
OTHER SOURCE(S):	MARPAT 137:247710			
GI				



AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20

for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.

IT	1-carbamoylpyrrolidine con	give the su
	388117-63-3P	388117-64-4P
	388117-66-6P	388117-67-7P
	388117-69-9P	388117-70-2P
	388117-72-4P	388117-73-5P
	388117-75-7P	388117-76-8P
	388117-78-0P	388117-79-1P
	388117-81-5P	388117-82-6P
	388117-84-8P	388117-85-9P
		388117-86-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

```


      (uses)
      (prepn. of aryl phenylheterocyclyl sulfides as cell
adhesion-inhibiting

```


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
antiinflammatory and immunosuppressive agents)  
RN 388117-63-3 CAPLUS  
CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS  
CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-65-5 CAPLUS  
CN Morpholine, 2,6-dimethyl-4-[6-[4-[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 388117-66-6 CAPLUS  
CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-67-7 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-68-8 CAPLUS  
CN Acetamide, N-ethyl-N-[1-[6-[4-[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-70-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-71-3 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS  
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-74-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-79-1 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS  
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-81-5 CAPLUS  
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-76-8 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 388117-77-9 CAPLUS  
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-87-1 CAPLUS  
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388118-57-8 CAPLUS  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388118-57-8 CAPLUS  
CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388118-58-9 CAPLUS  
CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:449662 CAPLUS  
DOCUMENT NUMBER: 137:33310  
TITLE: Preparation of anilino-pyrimidines as IKK inhibitors  
INVENTOR(S): Koia, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 194 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020195	A5	20020618	AU 2002-20195	20011205
PRIORITY APPLN. INFO.:			US 2000-251816P	P 20001206
			WO 2001-US46403	W 20011205
OTHER SOURCE(S):			MARPAT 137:33310	
GI				



AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)4COR9, (CH2)4CO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .10 to 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.

IT 434944-90-8P 434944-91-9P 434944-92-0P  
434944-96-4P 434944-99-7P 434945-00-3P

4/8/2003

Habte

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434945-01-4P 434945-04-7P 434945-05-8P  
 434945-27-4P 434945-75-2P 434945-76-3P  
 434949-28-7P 434949-29-8P 434949-31-2P  
 434949-33-4P 434949-35-6P 434949-36-7P  
 434949-38-9P 434949-40-3P 434949-42-5P  
 434949-44-7P 434949-47-0P 434949-50-5P  
 434949-53-8P 434949-56-1P 434949-68-5P  
 434949-71-0P 434949-74-3P 434949-77-6P  
 434949-79-8P 434949-81-2P 434949-83-4P  
 434949-85-6P 434949-87-8P 434949-91-4P  
 434949-94-7P 434949-95-8P 434949-96-9P  
 434949-97-0P 434949-98-1P 434949-99-2P  
 434950-03-5P 434950-04-6P 434950-05-7P  
 434950-06-8P 434950-07-9P 434950-08-0P  
 434950-09-1P 434950-10-4P 434950-11-5P  
 434950-12-6P 434950-13-7P 434950-14-8P  
 434950-15-9P 434950-16-1P 434950-17-2P  
 434950-18-3P 434950-19-4P 434950-20-5P  
 434950-21-6P 434950-22-7P 434950-23-8P  
 434950-24-9P 434950-25-1P 434950-26-2P  
 434950-27-3P 434950-28-4P 434950-29-5P  
 434950-30-6P 434950-31-7P 434950-32-8P  
 434950-33-9P 434950-34-1P 434950-35-2P  
 434950-36-3P 434950-37-4P 434950-38-5P  
 434950-39-6P 434950-40-7P 434950-41-8P  
 434950-42-9P 434950-43-1P 434950-44-2P  
 434950-45-3P 434950-46-4P 434950-47-5P  
 434950-48-6P 434950-49-7P 434950-50-8P  
 434950-51-9P 434950-52-1P 434950-53-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilino pyrimidines as IKK inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,

4-[[4-[[4-(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS


CN Benzamide, 4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Benzamide, 4-[[4-[[4-[[1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7  
 CMP C23 H25 N5 O3 S




CM 2

CRN 76-05-1  
 CMP C2 H F3 O2



RN 434945-01-4 CAPLUS


CN Benzamide, 4-[[4-[[4-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS


CN Benzamide, 4-[[4-[[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS

CN Benzamide, 4-[[4-[[4-(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 434944-96-4 CAPLUS

CN Benzamide, 4-[[4-[[4-(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)




RN 434944-99-7 CAPLUS

CN Benzamide, 4-[[4-[[4-[[1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-00-3 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434945-05-8 CAPLUS

CN Benzamide, 4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine, 4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS


CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-28-7 CAPLUS  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-31-2 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS  
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434949-40-3 CAPLUS  
 CN 4-Piperidinol, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS  
 CN Piperazine, 3-methyl-1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434949-36-7 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-38-9 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434949-44-7 CAPLUS  
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-47-0 CAPLUS  
 CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

4/8/2003


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-50-5 CAPLUS  
 CN Piperazine, 1-[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-53-8 CAPLUS  
 CN Piperazine, 1-[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 434949-56-1 CAPLUS  
 CN Piperazine, 1-[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-71-0 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-77-6 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-79-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 434949-68-5 CAPLUS  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-81-2 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-83-4 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[[4-[[4-(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

4/8/2003

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-04-6 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS  
 CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

Habt


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(2-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-97-0 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

pyrimidinyl]amino]benzoyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-06-8 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-07-9 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-08-0 CAPLUS  
 CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-09-1 CAPLUS  
CN Piperazine,  
1-(2-ethoxyethyl)-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-10-4 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[[4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-14-8 CAPLUS  
CN Piperazine,  
1-(2-ethoxyethyl)-4-[[4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-15-9 CAPLUS  
CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-33-1 CAPLUS  
CN 1-Piperazinepropanamine,  
N,N-dimethyl-4-[[4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-11-5 CAPLUS  
CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS  
CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-34-2 CAPLUS  
CN 4-Piperidinol, 1-[[4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-35-3 CAPLUS  
CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 434950-36-4 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS  
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-38-6 CAPLUS  
CN Piperazine, 1-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434950-43-3 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-44-4 CAPLUS  
CN Piperazine, 1-[[4-[[4-[(4-pyridinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS  
CN Piperazine, 3-methyl-1-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434950-40-0 CAPLUS  
CN Piperidine, 4-(1-pyrrolidinyl)-1-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-41-1 CAPLUS  
CN 4-Piperidinol, 1-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-42-2 CAPLUS  
CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS  
CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[[4-[(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
CN Piperazine, 1-[[4-[[4-[(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-[(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-48-8 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS  
 CN Piperazine, 1-methyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-50-2 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 434950-51-3 CAPLUS  
 CN 1-Piperazinepropanamine,  
 N,N-dimethyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN Benzoic acid, 4-[[4-[[4-(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-52-4 CAPLUS  
 CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS  
 CN Benzamide, N,N-dimethyl-4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)



IT 434950-65-9P 434950-68-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of anilinopyrimidines as IKK inhibitors)  
 RN 434950-65-9 CAPLUS  
 CN Benzoic acid,  
 4-[[4-[[4-(morpholinylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:449661 CAPLUS  
 DOCUMENT NUMBER: 137:33309  
 TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors  
 INVENTOR(S): Koia, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Paxnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 199 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205
OTHER SOURCE(S):			MARPAT 137:33309	
GI				



AB The title compds. (I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCOR9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4) having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 10 .mu.M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compds.

contg. one or more compds. of the above compds.  
 IT 434944-90-8P 434944-91-9P 434944-92-0P  
 434944-96-4P 434944-99-7P 434945-00-3P

Habte

4/8/2003

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434945-01-4P 434945-04-7P 434945-05-8P  
 434945-27-4P 434945-75-2P 434945-76-3P  
 434949-28-7P 434949-29-8P 434949-31-2P  
 434949-33-4P 434949-35-6P 434949-36-7P  
 434949-38-9P 434949-40-3P 434949-42-5P  
 434949-44-7P 434949-47-0P 434949-50-5P  
 434949-53-8P 434949-56-1P 434949-68-5P  
 434949-71-0P 434949-74-3P 434949-77-6P  
 434949-79-8P 434949-81-2P 434949-83-4P  
 434949-85-6P 434949-87-8P 434949-91-4P  
 434949-94-7P 434949-95-8P 434949-96-9P  
 434949-97-0P 434949-98-1P 434949-99-2P  
 434950-03-5P 434950-04-6P 434950-05-7P  
 434950-06-8P 434950-07-9P 434950-08-0P  
 434950-09-1P 434950-10-4P 434950-11-5P  
 434950-12-6P 434950-13-7P 434950-14-8P  
 434950-15-9P 434950-16-1P 434950-17-2P  
 434950-18-3P 434950-19-4P 434950-20-5P  
 434950-21-6P 434950-22-7P 434950-23-8P  
 434950-24-9P 434950-25-1P 434950-26-2P  
 434950-27-3P 434950-28-4P 434950-29-5P  
 434950-30-6P 434950-31-7P 434950-32-8P  
 434950-33-9P 434950-34-1P 434950-35-2P  
 434950-36-3P 434950-37-4P 434950-38-5P  
 434950-39-6P 434950-40-7P 434950-41-8P  
 434950-42-9P 434950-43-1P 434950-44-2P  
 434950-45-3P 434950-46-4P 434950-47-5P  
 434950-48-6P 434950-49-7P 434950-50-8P  
 434950-51-9P 434950-52-1P 434950-53-2P


RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilino pyrimidines as JNK pathway inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,

4-[[4-[[4-(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS

CN Benzamide, 4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Benzamide, 4-[[4-[[4-[[1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7

CMF C23 H25 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 434945-01-4 CAPLUS


CN Benzamide, 4-[[4-[[4-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS


CN Benzamide, 4-[[4-[[4-[[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS

CN Benzamide, 4-[[4-[[4-(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434944-96-4 CAPLUS

CN Benzamide, 4-[[4-[[4-(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434944-99-7 CAPLUS

CN Benzamide, 4-[[4-[[4-[[1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-00-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434945-05-8 CAPLUS

CN Benzamide, 4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine, 4-[[4-[[4-[[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS


CN Piperazine, 1-acetyl-4-[[4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-28-7 CAPLUS  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS  
 CN Piperazine, 1-acetyl-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-31-2 CAPLUS  
 CN Piperazine, 1-(1-methylethyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS  
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434949-40-3 CAPLUS  
 CN 4-Piperidinol, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS  
 CN Piperidine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Habe

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS  
 CN Piperazine, 3-methyl-1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434949-36-7 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-38-9 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434949-44-7 CAPLUS  
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-47-0 CAPLUS  
 CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


4/8/2003




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-50-5 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-53-8 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 434949-56-1 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-71-0 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-77-6 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-79-8 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 434949-68-5 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-81-2 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-83-4 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS  
 CN Piperazine, 1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(hexahydro-1H-azepin-1-ylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS  
CN Piperazine, 1-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-04-6 CAPLUS  
CN Piperazine, 1-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-

Habte


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(2-methyl-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(3-methyl-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-97-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(3-methyl-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-(3-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-06-8 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-07-9 CAPLUS  
CN Piperazine, 1-[[4-[[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-08-0 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-09-1 CAPLUS  
 CN Piperazine,  
 1-(2-ethoxyethyl)-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-2-pyrimidinylamine]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-10-4 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS  
 CN Piperazine, 3,5-dimethyl-1-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-14-8 CAPLUS  
 CN Piperazine,  
 1-(2-ethoxyethyl)-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-2-pyrimidinylamine]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-15-9 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-33-1 CAPLUS  
 CN 1-Piperazinepropanamine,  
 N,N-dimethyl-4-[[4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-11-5 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[[4-[[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-34-2 CAPLUS  
 CN 4-Piperidinol, 1-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-35-3 CAPLUS  
 CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 434950-36-4 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS  
CN 1-Piperazineacetamide,  
N-(1-methylethyl)-4-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-38-6 CAPLUS  
CN Piperazine, 1-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A



RN 434950-43-3 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-44-4 CAPLUS  
CN Piperazine, 1-[[4-[[4-[[4-((4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS  
CN Piperazine, 3-methyl-1-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (3R) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434950-40-0 CAPLUS  
CN Piperidine, 4-(1-pyrrolidinyl)-1-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-41-1 CAPLUS  
CN 4-Piperidinol, 1-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-42-2 CAPLUS  
CN Piperazine, 1-[[3,5-dimethyl-4-isoxazolyl]carbonyl]-4-[[4-[[4-[[4-((tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS  
CN Piperazine, 1-(2-ethoxyethyl)-4-[[4-[[4-[[4-((phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
CN Piperazine, 1-[[4-[[4-[[4-((phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-[[4-((tetrahydro-2-furanyl)methyl)- (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[[4-[[4-[[4-((phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-48-8 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[[4-[[4-[[4-((phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS  
CN Piperazine, 1-methyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-50-2 CAPLUS  
CN Piperazine, 1-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 434950-51-3 CAPLUS  
CN 1-Piperazinepropanamine,  
N,N-dimethyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN Benzoic acid, 4-[[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS  
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434950-53-5 CAPLUS  
CN Benzamide, N,N-dimethyl-4-[[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 434950-65-9P 434950-68-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of anilinopyrimidines as JNK pathway inhibitors)  
RN 434950-65-9 CAPLUS  
CN Benzoic acid,  
4-[[4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN Benzoic acid, 4-[[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:31429 CAPLUS  
DOCUMENT NUMBER: 136:102394  
TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
PATENT ASSIGNEE(S): Abbott Lab., USA  
SOURCE: PCT Int. Appl., 135 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-606717 A 20000629				
OTHER SOURCE(S): MARPAT 136:102394				
GI				




AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-P(F3C)C6H3COME, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT 388118-57-8P 388118-58-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)  
RN 388118-57-8 CAPLUS


Habte

4/8/2003

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 4-(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388118-58-9 CAPLUS  
 CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-63-3 CAPLUS  
 CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-64-4 CAPLUS  
 CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-68-8 CAPLUS  
 CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-70-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS  
 CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-66-6 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-67-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-71-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-73-5 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-74-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-76-8 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-80-4 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-81-5 CAPLUS  
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-77-9 CAPLUS  
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-78-0 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 388117-79-1 CAPLUS  
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS  
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
 CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:612432 CAPLUS  
 DOCUMENT NUMBER: 117:212432  
 TITLE: Studies on cerebral protective agents. I. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities  
 AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshie; Katsuta, Kiyotaka; Kamitani, Toshiharu; Takasugi, Hisashi  
 CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan  
 SOURCE: Chemical & Pharmaceutical Bulletin (1992), 40(6), 1452-61  
 CODEN: CPBTAL; ISSN: 0009-2363  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Novel 4-arylpyrimidine deriva. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compda., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O2NC6H4) has ALP activity (73% inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of vitamin E.  
 IT 103293-67-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn., antianoxic and antilipid peroxidn. activities of)  
 RN 103293-67-0 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-[2-[[4-(chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

4/8/2003




L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1986:572492 CAPLUS  
DOCUMENT NUMBER: 105:172492  
TITLE: Pyrimidine derivatives  
INVENTOR(S): Takaya, Takao; Takasugi, Hieashi; Kuno, Atsushi;  
Sugiyama, Yoshie  
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 192 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
FI 8502796	A	19860120	FI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
FI 8503698	A	19860402	FI 1985-3698	19850926
EP 177287	A2	19860409	EP 1985-306880	19850927
EP 177287	A3	19861126		
EP 177287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58897	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001
PRIORITY APPLN. INFO.:				
			GB 1984-18380	19840719
			GB 1984-24711	19841001
			GB 1985-9623	19850415
			GB 1985-9633	19850415
			EP 1985-305143	19850718
			EP 1985-306880	19850927

G1

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Pyrimidines I (R = substituted aryl; R1 = CO<sub>2</sub>H, esterified CO<sub>2</sub>H, alkanoyl, etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prepd., and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine deriv. II was heated with MnO<sub>2</sub> to give I (R = 4-pyridyl, R1 = CO<sub>2</sub>Et, R2 = Me, R3 = Ph). II was prepd. from an .alpha.- (arylmethylene)acetosuccinate ester and an amidine.  
IT 103293-67-0P  
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of. for treatment of cerebrovascular disease)  
RN 103293-67-0 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.05

176.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.91

-3.91

STN INTERNATIONAL LOGOFF AT 17:34:56 ON 10 APR 2003